

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 86302390.9

(51) Int. Cl. 4: **C07D 487/04**, **A61K 31/505**,
/(C07D487/04,239:00,231:00)

(22) Date of filing: 01.04.86

(30) Priority: 05.04.85 US 720437

(43) Date of publication of application:
 17.12.86 Bulletin 86/46

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: **WARNER-LAMBERT COMPANY**
201 Tabor Road
Morris Plains New Jersey 07950(US)


(72) Inventor: **Hamilton, Harriet W.**
234 Park Street
Chelsea Michigan 48118(US)

(74) Representative: **Jones, Michael Raymond et al**
HASELTINE LAKE & CO. Hazlitt House 28
Southampton Buildings Chancery Lane
London WC2A 1AT(GB)

(54) **5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones, process for preparing the compounds and pharmaceutical compositions comprising the compounds.**

(57) The present invention relates to novel 5-substituted pyrazolo[4,3-d]pyrimidine-7-one compounds of

formula:



EP 0 201 188 A2

and compositions, methods of use and processes to make the compounds. The novel compounds are useful in the treatment of cardiovascular disorders, such as heart failure or cardiac insufficiency. The novel compounds bind adenosine receptors and selectively inhibit phosphodiesterase.

5-SUBSTITUTED PYRAZOLO[4,3-d] PYRIMIDINE-7-ONES, PROCESS FOR PREPARING THE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS

The present invention provides novel 5-substituted pyrazolo[4,3-d]pyrimidine-7-one compounds. The structurally novel class of compounds contain a ring system numbered clockwise starting with the nitrogen in the diazole substituent nearest the pyrimidinone ring fused thereto as shown by Formula XL. In particular, this invention relates to a combination of substituents on the ring system XL in the one, three, and five position not hitherto known referred to above as 5-substituted pyrazolo[4,3-d]pyrimidine-7-one compounds.

The present invention also relates to novel methods for the synthesis and use of the novel 5-substituted pyrazolo[4,3-d]pyrimidine-7-one compounds disclosed herein. The disclosure particularly relates to the novel compounds for use in the treatment of cardiovascular disorders, such as heart failure, or cardiac insufficiency. The novel compounds are found to bind to an adenosine receptor and thus function as antagonists to adenosine or adenosine receptor agonists. Of special interest is the selective inhibition of phosphodiesterase by the novel compounds of the present invention.

Various references disclose compounds having the pyrazolo[4,3-d]pyrimidine-7-one ring system shown by Formula XL. For Example, 1,3-dimethyl-1H-pyrazolo [4,3-d]pyrimidine-7-(6H)-ones useful as anticonvulsants, sedatives, and antiinflammatory and gastric antisecretory agents are disclosed in US Patent Number 3,939,161 assigned to Abbott Laboratories. However, the disclosed pyrazolo[4,3-d]pyrimidine-7-(6H)-one is limited at the five position on the ring to hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, morpholinomethyl, piperidinomethyl, methoxymethyl, N-methylpiperazinomethyl, benzylthiomethyl, carbethoxy or p-chlorophenoxymethyl.

In Liebigs. Ann. Chem., 7131, 149 (1968) a synthesis of 1-phenyl-5-substituted pyrazolo[4,3-d]pyrimidine-7-ones is taught where the substituent at the five position is methyl, phenyl, benzyl, paramethylbenzyl, naphthyl, cyanoalkyl, or ethoxyethyl. The synthesis does not include any compounds which do not require a phenyl group in the one position. Further, no utility is taught.

Of less interest are compounds having the 3,4-d ring system and shown by the Formula XX as disclosed in Synthesis, p. 727 (1981) and shown by the Formula XXX as disclosed in Bull. Chem. Soc. Japan, 52(1), 208 (1979).

None of the compounds as disclosed and discussed above teach the novel compounds of the present invention having the present combination of substituents on the ring system of Formula XL.

The present invention relates to a novel compound of Formula I wherein R₁ is lower alkyl of from one to six carbons, inclusive, lower alkylene of from one to six carbons, inclusive, lower hydroxyalkyl of from one to six carbons, inclusive, lower hydroxyalkylene of from two to six carbons, inclusive, lower aminoalkyl of from one to six carbons, inclusive, or lower aminoalkylene of from two to six carbons, inclusive; n is 0-4; an Ar is R₂ or 2, 3, or 4-pyridyl wherein X, Y, and Z are independently - (1) hydrogen; (2) lower alkyl of from one to six carbons, inclusive; (3) halogen; (4) hydroxyl; (5) lower alkoxy of from one to six carbons, inclusive; - (6) nitro; (7) amino; (8) NR'R' ' wherein R' and R' ' are each independently (a) hydrogen or (b) lower alkyl of from one to six carbons, inclusive, optionally substituted by (i) amino, (ii) morpholino, or (iii) cycloalkyl of from five to seven carbons, inclusive; (9) sulfonyl; or (10) -SO₂NR'R' ' wherein R' and R' ' are as defined above with the proviso that not all of X, Y, and Z can be nitro, amino, or NR'R' ' at once, or a pharmaceutically acceptable salt thereof.

A compound of Formula I may exist in one of two tautomers as shown by the formula I, \rightleftharpoons I₂.

The novel compounds of the present invention having the Formula I are two embodiments, i.e., one wherein Ar is R₂ and the second wherein Ar is 2-, 3-, or 4-pyridyl.

The preferred embodiment is a compound of Formula I wherein Ar is R₂, wherein R₂ is as defined above. Within the preferred embodiment is a more preferred embodiment of Formula I wherein R₁ is ethyl or methyl and n is 0 or 1. The most preferred embodiments are a compound of Formula I wherein R₁ is methyl, n is 1, and Ar is phenyl, i.e., 1,3-dimethyl-5-benzylpyrazolo[4,3-d]pyrimidine-7-one, or a pharmaceutically acceptable salt thereof; a compound of Formula I wherein Ar is 4-chlorophenyl, n is 0, R₁ is methyl; i.e., 1,3-dimethyl-5-[4-chlorophenyl]-pyrazolo[4,3-d]pyrimidine-7-one or a pharmaceutically acceptable salt thereof; and a compound of Formula I wherein Ar is phenyl, R₁ is ethyl, n is 0; i.e., 1-ethyl-3-methyl-5-[4-[N-2-(dimethylamino)ethyl]-benzenesulfonamide]pyrazolo[4,3-d]pyrimidine-7-one or a pharmaceutically acceptable salt thereof.

The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of the above Formula I with a pharmaceutically acceptable carrier and to a method of treating mammals, including humans, by administering to such mammals having a need for the treatment an effective amount of a compound of Formula I as defined above.

DETAILED DESCRIPTION OF THE INVENTION

In the compounds of the Formula I, the term lower alkyl or from one to six carbons, inclusive, means a straight or branched alkyl group, such as, for example, methyl, ethyl, propyl, butyl, amyl, hexyl, and isomers thereof. The term alkylene of from two to six carbons, inclusive, means a straight or branched alkylene group, such as, for example, ethylene, propylene, butylene, amylene, hexylene, and isomers thereof. Hydroxyalkyl of from one to six carbons, inclusive, means alkyl as defined above having a hydroxy substituent. Hydroxyalkylene of from two to six carbons, inclusive, means alkylene as defined above having an hydroxy substituent. Likewise, aminoalkyl and aminoalkylene are alkyl or alkylene as defined above having an amino substituent. No limitation as to the location of the substituent hydroxy or amino is included.

The compounds of Formula I are useful both in the free base form and in the form of acid addition salts. Both forms are within the scope of the invention. In practice, use of the salt form amounts to use of the base form. Appropriate pharmaceutically acceptable salts within the scope of the invention are those derived from mineral acids, such as hydrochloric acid, sulfuric acid, and the like; and organic acids, such as ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like, giving the hydrochloride, sulfamate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate salts, respectively.

Certain compounds of this invention, e.g., those with hydroxyl-bearing or amino-bearing R₁, and those lower alkyl of from one to six carbons, inclusive, optionally substituted by amino, morpholine, or cycloalkyl of from five to seven carbons, inclusive, which are so distributed, have asymmetric carbon atoms and such compounds can exist as enantiomers or diastereomers. Thus, all names and representations of compounds as used herein shall include all such isomers and racemic mixtures thereof.

Generally, compounds of Formula I are conveniently synthesized by methods shown in Scheme I and Scheme II.

In Scheme I the substituted pyrazole of Formula VI; prepared by methods shown in US Patent Number 3,553,209, is treated with a mixture of sulfuric acid and fuming nitric acid at a temperature of about 80-100°C to effect nitration. The amide of Formula IV is synthesized from the acid in the usual manner by treating with thionyl chloride followed by pouring the resulting acid chloride into icy ammonium hydroxide. This nitro-amide pyrazole is converted to the amine of Formula III by catalytic hydrogenation utilizing Raney nickel as a catalyst using conditions appropriate for hydrogenation. The substituted pyrazolo-aminoamide of Formula III can then be converted to the product in one of two ways: Stirring with the appropriately substituted carboxylic acid in polyphosphoric acid at a temperature of about 140°C for 4 to 24 hours to obtain the compound of Formula I; alternatively it can be treated first with the appropriately substituted acid chloride in an inert solvent such as methylene chloride in the presence of base to afford the bisamide of Formula II, which is then cyclized with polyphosphoric acid to give the compound of Formula I.

In Scheme II, the substituted nitrochloropyrazole of Formula XI; also prepared by method shown in US Patent Number 3,553,209, is treated with potassium cyanide to give the nitro-cyanopyrazole of Formula IX, followed by reduction of the nitro group to an amine of Formula VIII by catalytic hydrogenation using Raney nickel as a catalyst. This substituted cyanoamino-pyrazole of Formula VIII is stirred with the appropriately substituted acid chloride in an inert solvent in the presence of a base to afford the cyanopyrazolo-amide of Formula VII, which can be cyclized by treatment with basic hydrogen peroxide at an elevated temperature of from about 80 to 100°C to give the final compound of Formula I.

The products of the reactions described herein are isolated by conventional means such as extraction, distillation, crystallization, chromatography, and the like.

The acid addition salts of the Formula I compounds are prepared by reacting the amino base with the stoichiometric equivalent of the acid corresponding to the pharmacologically acceptable acid addition salt.

The compounds of this invention may also exist in hydrated or solvated forms.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

By virtue of the activity determined by the test procedures as described below the compounds of Formula I are useful in treating symptoms in mammals including humans associated with desirable effects recognized as stimulation of the central nervous system, reversing bronchoconstriction, stimulation of the cardiac system, action of cardiotonic agents. A physician or veterinarian of ordinary skill readily determines a subject who is exhibiting symptoms responding to such desirable effects. Regardless of the route of administration selected, the compounds of the present invention are formulated into pharmaceutically acceptable dosage forms by conventional methods known to the pharmaceutical art.

The compounds can be administered in such oral unit dosage forms as tablets, capsules, pills, powders, or granules. They also may be administered rectally, vaginally in such forms as suppositories or bougies; they may also be introduced parenterally (e.g., subcutaneously, intravenously, or intramuscularly), using forms known to the pharmaceutical art. They are also introduced directly to an affected area, (e.g., by inhalation). In general, the preferred route of administration is orally.

An effective quantity of the compound is employed in treatment. The dosage regimen for preventing or treating the symptoms as described above by the compounds of this invention is selected in accordance with a variety of factors including the type, age, weight, sex and medical condition of the mammal, the severity of the symptoms, the route of administration, and the particular compound employed. An ordinarily skilled physician or veterinarian will readily determine and prescribe the effective amount to prevent or arrest the progress of the condition having the symptoms as described herein.

Daily dosages of the compounds of the invention are ordinarily in the area of 0.1 mg/kg up to at least 100 mg/kg per dose orally, preferably 1 to 50 mg/kg orally and are given from one to four times daily or as needed. When other forms of administration are employed equivalent doses are administered. When dosages beyond 200 mg/kg are employed, care should be taken with each subsequent dose to monitor possible toxic effects.

PHARMACOLOGICAL EVALUATION

The compounds of Formula I have been found to possess affinity for adenosine receptors (designated A, for convenience).

Adenosine Receptor Binding -A. Receptor Affinity - (RBA1)

5 Preparation of Membranes

Whole brain minus cerebellum and brainstem from male Long Evans rats (150-200 g) was homogenized in 30 volumes of ice-cold 0.05 M Tris-HCl buffer pH 7.7 using a Brinkman Polytron PT-10, (setting number 6 for 20 seconds) and centrifuged for ten minutes at 20,000 x g (Sorvall RC-2), 4°C. The supernatant was discarded, and the pellet was resuspended and centrifuged as before. The pellet was resuspended in 20 ml Tris-HCl buffer containing two International Units/ml of adenosine deaminase (Sigma type III from calf intestinal mucosa), incubated at 37°C for 30 minutes, then subsequently at 0°C for ten minutes. The homogenate was again centrifuged, and the final pellet was resuspended in ice-cold 0.05 M Tris-HCl buffer pH 7.7 to a concentration of 20 mg/ml original wet tissue weight and used immediately.

25 Assay Conditions

Tissue homogenate (10 mg/ml) was incubated in 0.05 M Tris-HCl buffer pH 7.7 containing 1.0 nM [³H]-N⁶-cyclohexyladenosine (³H)-CHA) with or without test agents in triplicate for one hour at 25°C. Incubation volume was 2 ml. Unbound [³H]-CHA was separated by rapid filtration under reduced pressure through Whatman glass fiber (GF/B) filters. The filters were rinsed three times with 5 ml of ice cold 0.05 M Tris-HCl buffer pH 7.7. The radio-labeled ligand retained on the filter was measured by liquid scintillation spectrophotometry after shaking the filters for one hour or longer on a mechanical shaker in 10 ml of Beckman Ready-Solv HP scintillation cocktail.

Calculations

Nonspecific binding was defined as the binding which occurred in the presence of 1 mM theophylline. The concentration of test agent which inhibited 50% of the specific binding (IC₅₀) was determined by nonlinear computer curve fit. The Scatchard plot was calculated by linear regression of the line obtained by plotting the amount of radioligand bound (mmoles/gram of tissue) versus

$$\left[\frac{\text{bound radioligand}}{\text{free radioligand}} \right].$$

Since the amount of radioligand bound was a small fraction of the total amount added, free radioligand was defined as the concentration (nM) of radioligand added to the incubation mixture. The

Hill coefficient was calculated by linear regression of the line obtained by plotting the log of the bound radioligand vs the log of the

$$\left[\frac{\text{bound radioligand}}{B_{\max} - \text{bound radioligand}} \right]$$

The maximal number of binding sites (B_{\max}) was calculated from the Scatchard plot.

The IC_{50} values (nM) for adenosine A₁ receptor affinity is reported in Table 1.

TABLE 1
Receptor Binding

Example	RBA-1 (nM)
1	13,100
2	953
3	237
4	3,090
5	670
6	1,020
7	408
8	417
9	880
10	463
11	385
12	1,540
13	1,200
14	10,000
15	887
16	1,920
17	5,430
18	8,500
19	314
20	13,000
21	684
22	8,200

Phosphodiesterase (PDE) Inhibition

Isolation of Multiple Molecular Forms of Phosphodiesterase

The method of Thompson, et al (Thompson, W. J., Terasaki, W. L., Epstein, P. M., Strada, S. J., Adv. Cyclic Nucleotide Res., 10:69-92, 1979), with minor modifications, was used to isolate phosphodiesterases from vascular smooth muscle.

45 Bovine coronary arteries (right, anterior descend-
ing, and left circumflex arteries) from hearts ob-
tained from a local slaughterhouse were used for
these studies. Arteries from two hearts were used
for each isolation. Hearts were kept on ice and the
50 arteries were dissected within two hours after the
animals were sacrificed. After removing all fat and
connective tissue, the arteries were everted, cut
into cubes with a single edge razor blade and
homogenized with a Brinkman Polytron three times
55 at a rheostat setting of 10.0 in four volumes of the
PDE isolation buffer (10 mM Tris-HCl/pH 7.5, 2mM

MgCl₂, and 1 mM dithiothreitol). The resulting homogenate was sonicated (30 sec/ml homogenate) and then centrifuged at 30,000 xg for 20 minutes. This and all subsequent procedures were performed at 4°C. The resulting supernatant was filtered through four layers of gauze, and applied to a DEAE-cellulose column (30 x 1.5 cm), prepared as described by Cheung (Cheung, W. Y., Biochim. Biophys. Acta, 191:303-315, 1969), and equilibrated with freshly prepared 70 mM sodium acetate/5 mM 2-mercaptoethanol (pH 6.5). The column was then washed with 2-3 bed volumes of sodium acetate/2-mercaptoethanol, after which the phosphodiesterases were eluted from the column using a continuous 70-1,000 mM sodium acetate gradient (pH 6.5, containing 5 mM 2-mercaptoethanol; total volume 400 ml). The flow rate was approximately equal to 25 ml/hr. Eight ml fractions were collected and assayed for cyclic AMP and cyclic GMP-phosphodiesterase activity in the presence and absence of 0.1 units of calmodulin and 10 mM CaCl₂. Appropriate fractions were pooled and dialyzed against 70 mM sodium acetate/5 mM 2-mercaptoethanol for 20 hours.

Following complete separation, the combined phosphodiesterase fractions were concentrated to 14% of the original volume using an Amicon ultrafiltration cell fitted with a UM-10 membrane, ac-

cording to the method of Wells, et al (Wells, J. N., Baird, C. E., Wu, Y. J., Hardman, J. G., Biochim. Biophys. Acta, 384:430-442, 1975). Following concentration, the protein was then diluted to 65% with ethylene glycol monoethyl ether, and stored at -20°C. No significant change in hydrolytic activity was observed with storage up to six weeks.

Measuring Phosphodiesterase Activity

Phosphodiesterase activity was measured as described previously (Weishaar, P. E., Quade, M., Boyd, D., Schenden, J., Mark, S. S., Kaplan, H. R., Drug Devel. Res., 3:517-534, 1983), in a reaction medium containing 40 mM Tris-HCl (pH 8.0), 5 mM MgCl and 4 mM 2-mercaptoethanol. Unless otherwise noted, the concentration of substrate (³H-cyclic AMP or ³H-cyclic GMP) was 1.0 μM. All agents examined were dissolved in dimethyl sulfoxide (DMSO). Final concentration of the reaction medium was either 2.5% (cardiac and platelet studies) or 1.25% (smooth muscle studies). This concentration of DMSO produced an approximately 10% inhibition of enzyme activity.

TABLE 2

Example	Type 1		Type 3
	Phosphodiesterase		Phosphodiesterase
	% Inhibition	% Inhibition	% Inhibition
	of hydrolysis of 3H-cAMP at 10 ⁻⁵ M	of hydrolysis of 3H-cGMP at 10 ⁻⁵ M	of hydrolysis of 3H-cAMP at 10 ⁻⁵ M
1	80	71	23
2	5	13	20
3	33	19	55
9	16	6	1
10	12	1	-9
11	19	15	32
12	6	9	33
13	30	18	50
15	5	3	0
18	7	5	7
19	16	12	5
4	6	4	3
5	29	29	56
6	6	14	35
7	7	11	13
8	14	15	15
16	10	17	17
17	15	26	17

The usefulness of the compounds of the present invention as cardiotonic agents is demonstrated by their effectiveness in standard pharmacological test procedures, for example, in causing a significant increase in the myocardial contractility in the pentobarbital-anesthetized dog with low or minimal changes in heart rate and blood pressure. This test procedure is described in the following paragraphs.

⁴⁵ Test for In Vivo Myocardial Inotropic Activity in Anesthetized Dog (CVAD)

⁵⁰ This screen consists of determining the effects of increasing intravenous doses of compound on myocardial contractility (dP/dt max of left ventricular blood pressure), heart rate, and aortic blood pressure of the pentobarbital-anesthetized dog.

⁵⁵

Methods

Adult mongrel dogs of either sex are anesthetized with pentobarbital, 35 mg/kg, IV, and are subsequently maintained under anesthesia with a continuous infusion of pentobarbital, 3.5 mg/kg/hour. The trachea is intubated but the animals are permitted to breathe spontaneously. A cannula is inserted into the femoral vein for administering test agents. A Miller catheter tip pressure transducer or a fluid filled catheter is inserted into the ascending aorta via the femoral artery for measuring aortic blood pressure. A Miller catheter tip pressure transducer is passed into the left ventricle via the left carotid artery for measuring left ventricular blood pressure. Needle electrodes are placed subcutaneously for recording a lead II electrocardiogram (ECG).

Left ventricular and aortic blood pressures are recorded on a strip chart recorder. Heart rate, using a biotachometer triggered from the R wave of the ECG, and the first derivative of left ventricular blood pressure (dP/dt), obtained with a differen-

tiator amplifier coupled to the corresponding pressure amplifier, are also recorded. A period of at least 30 minutes is utilized to obtain control data prior to administration of test compound.

Depending on solubility, the compounds are dissolved in 0.9% saline solution or in dilute HCl or NaOH (0.1 to 1.0 N) and are diluted to volume with normal saline. Ethanol or dimethylacetamide can be used as solvents if adequate dilutions can be made. Appropriate vehicle controls are administered when needed.

Each dose of the test compound is administered in a volume of 0.1 mg/kg over a period of one minute.

When tested by the above-described Anesthetized Dog Procedure, the compounds of the present invention, for example, compound Ia of Example 1, when administered intravenously at about 0.01 to 0.31 mg/kg cause dose related significant increases in cardiac contractility with only low or minimal changes in heart rate and a moderate reduction in blood pressure. Accordingly, the compounds of the present invention are also useful as antihypertensive agents.

The results are summarized in the following table.

TABLE 3
Percent Change

Example	Dose (mg/kg)	Myocardial Contractility	Heart Rate	Blood Pressure
1	0.00			
	0.10	+8	+2	+1/0
	0.31	+12	+3	0/-1
	1.00	+23	+6	-3/-5
	3.10	+42	+14	-4/-7
	10.00	+95	+38	-17/-25

TABLE 3
Percent Change (Cont'd)

Example	Dose (mg/kg)	Myocardial Contractility	Heart Rate	Blood Pressure
2	0.00			
	0.10	+4	+1	0
	0.31	+7	+1	+1/0
	1.00	+53	+28	+4/6
	3.10	+121	+49	+5/+6
3	0.00			
	0.10	+12	+4	+2
	0.30	+20	+7	+2
	1.00	+47	-1	+2
	3.10	+91	+16	+8
4	0.00			
	0.10	+2	0	0/0
	0.31	+7	+1	-1/-1
	1.00	+27	+4	0/-1
	3.10	+55	+9	-1/-5
5	0.00			
	0.10	+10	+7	2
	1.00	+77	+43	1
	3.10	+100	+50	1
6	0.00			
	0.10	+4	-1	+5/+5
	0.31	+3	-4	+8/+8
	1.00	+20	7	+12/+12
	3.10	+45	37	0/-1

TABLE 3
Percent Change (Cont'd)

Example	Dose (mg/kg)	Myocardial Contractility	Heart Rate	Blood Pressure
8	0.00			
	0.10	+7	+5	-1
	0.30	+10	+5	0
	1.00	+20	+6	+3
	3.10	+22	+10	+3
	10.00	+82		
9	0.00			
	0.10	+4	1	+3/+3
	0.31	+5	0	+3/+3
	1.00	+4	-3	+3/+4
	3.10	+2	1	+3/+5
11	0.00			
	0.10	+9	+1	1/1
	0.31	+17	+3	5/3
	1.00	+25	+5	1/0
	3.10	+66	+15	-7/-11
12	0.00			
	0.10	-1	-8	4/-1
	0.31	-19	-10	-11/-7
	1.00	-12	-8	-9/-6
13	0.00			
	0.10	6	2	-2
	0.30	5	4	-4
	1.00	-7	-3	-7
	3.10	6	-3	-12
	10.00	101		

TABLE 3
Percent Change (Cont'd)

Example	Dose (mg/kg)	Myocardial Contractility	Heart Rate	Blood Pressure
14	0.00			
	0.10	2	2	-1/0
	0.31	4	4	-2/-2
	1.00	10	14	-2/-3
	3.10	34	27	-5/-8
15	0.00			
	0.10	8	7	1/2
	0.31	10	7	-1/-1
	1.00	13	9	-1/-1
	3.10	13	12	1/2
16	0.00			
	0.10	2	1	-1/-1
	0.31	-1	-1	1/3
	1.00	-1	-2	1/2
22	0.00			
(Test 1)	0.01	11	-1	1/0
	0.03	12	-1	0/-1
	0.10	17	-4	-2/-5
	0.30	6	-10	-7/-12
	1.00	14	-12	-3/-6
(Test 2)	0.00			
	0.01	-12	-14	0/-2
	0.03	-13	-17	-1/-4
	0.10	-15	-21	-1/-4
	0.31	-14	-22	-2/-4
	1.00	2	-11	-2/-5

TABLE 3
Percent Change (Cont'd)

Example	Dose (mg/kg)	Myocardial Contractility	Heart Rate	Blood Pressure
23	0.00			
	0.01	+5	+1	2/2
	0.31	+15	+3	3/4
	1.00	+22	+6	-2/-3

The operation of this invention is further elaborated by the representative examples below.

EXAMPLE 1

1,3-Dimethyl-5-benzylpyrazolo[4,3-d]pyrimidine-7-one

The compound was prepared as in Example 6A using 1.11 g of 1,3-dimethyl-5-cyano-pyrazole-4-N-benzyl-carboxamide, 0.26 g sodium hydroxide and 1 ml 30% H₂O₂.

Analysis as: C₁₈H₁₆N₄O.11/8 H₂O

Calcd: C, 61.24; H, 5.97; N, 20.41

Found: C, 61.54; H, 5.64; N, 20.18

The starting material was prepared as in Example 6A using phenylacetic acid chloride, mp 184-185°C.

EXAMPLE 2

1,3-Dimethyl-5-(4-pyridyl)-pyrazolo[4,3-d]pyrimidine-7-one

The compound was prepared as in Example 6B using 5 g of 1,3-dimethyl-4-aminopyrazole-5-carboxamide and 3.99 g isonicotinic acid. After pouring into ice water the aqueous solution was treated with 25% potassium hydroxide to give a precipitate. This was collected and recrystallized in

ethanol to give the product, mp 321-322°C.

Analysis as: C₁₇H₁₁N₅O

Calcd: C, 59.74; H, 4.60; N, 29.03

Found: C, 59.45; H, 4.53; N, 28.81

EXAMPLE 3

1-Ethyl-3-methyl-5-(4-pyridyl)pyrazolo[4,3-d]pyrimidine-7-one

The starting bis-amide was prepared as described in Example 4 using 4.78 g of 1-ethyl-3-methyl-4-amino-pyrazole-5-carboxamide, 5.06 isonicotanoyl chloride hydrochloride, and 5.74 g triethylamine. This compound was cyclized as in Example 6B using 300 g polyphosphoric acid. The aqueous solution was neutralized with 50% sodium hydroxide, the resulting precipitate collected and then recrystallized in ethanol, mp 257-260°C.

Analysis as: C₁₉H₁₅N₅O

Calcd: C, 61.17; H, 5.13; N, 27.43

Found: C, 60.91; H, 5.15; N, 27.66

EXAMPLE 4

1,3-Dimethyl-5-(3-pyridyl)pyrazolo[4,3-d]pyrimidine-7-one

Two g. of 1,3-dimethyl-4-amino-pyrazole-5-carboxamide, 2.31 g nicotinic acid chloride hydrochloride and 3.03 g triethylamine were combined in chloroform and stirred at reflux for 18 hours. The solution was cooled and washed with water. A precipitate formed in the aqueous layer, which was filtered and dried to give the bis-amide, mp 209-211°C. An additional crop was isolated by pouring the chloroform solution over ice, then filtering the resulting precipitate, mp 209-211°C.

The bis-amide was cyclized in 75 g of polyphosphoric acid at 145°C for four hours. This was poured into rapidly stirred ice water, and then neutralized to pH 7-8 with 50% sodium hydroxide. The resulting precipitate was collected, and recrystallized in ethanol-water to give the product, mp 309-309.5°C.

Analysis as: $C_{12}N_{11}O.0.1 H_2O$.

Calcd: C, 59.30; H, 4.64; N, 28.81

Found: C, 59.57; H, 4.91; N, 28.52

EXAMPLE 5

1-Ethyl-3-methyl-5-phenylpyrazolo[4,3-d]pyrimidine-7-one

The starting bis-amide was prepared in an analogous manner to the starting material for Example 6A using 5 g of 1-ethyl-3-methyl-4-aminopyrazole-5-carboxamide, 4.18 g benzoyl chloride and 3 g of triethylamine, mp 219-220°C.

This was cyclized as in Example 6B using 5.12 g bis-amide and 150 g polyphosphoric acid. The product was filtered directly from the ice water solution, mp 218-221°C. Analysis as: $C_{14}H_{14}N_4O.0.5 H_2O$

Calcd: C, 63.86; H, 5.74; N, 21.28 Found: C, 64.17;

H, 5.48; N, 21.30

EXAMPLE 6 -METHOD A (SCHEME 2)

1,3-Dimethyl-5-phenylpyrazolo[4,3-d]pyrimidine-7-one

Two-tenths g of sodium hydroxide was dissolved in 30 ml water and heated to 40°C. Eight-tenths ml of 30% hydrogen peroxide was added, followed by 0.77 g 1,3-dimethyl-5-cyanopyrazole-4-N-phenylcarboxamide. The mixture was heated to 80° for 4.5 hours, then cooled and acidified with glacial acetic acid. A white precipitate formed, which was filtered and recrystallized from ethanol to give the product, 1,3-dimethyl-5-phenylpyrazolo[4,3-d]pyrimidine-7-one, mp 269-271°C.

Analysis as: $C_{13}H_{12}N_4O.0.25 H_2O$

Calcd: C, 63.86; H, 5.24, N, 22.91

Found: C, 63.74; H, 5.33; N, 22.74

Starting material for Example 6 -1,3-dimethyl-5-cyanopyrazole-4-N-phenylcarboxamide

One g, 1,3-Dimethyl-4-amino-5-cyanopyrazole and 1 g benzoyl chloride were stirred with 0.71 g triethylamine in methylene chloride for 14 hours. The reaction mixture was washed with 5% aqueous HCl, dried over magnesium sulfate, then concentrated to a pale orange solid. This was recrystallized from chloroform/methanol to yield 1,3-dimethyl-5-cyanopyrazole-4-N-phenylcarboxamide, mp 212-213°C.

EXAMPLE 6 -METHOD B (SCHEME 1)

Five g 1,3-dimethyl-4-aminopyrazole-5-carboxamide, and 3.96 g benzoic acid were combined in 50 g polyphosphoric acid at 80°C. Heated to 140°C for six hours, then cooled, and poured into ice water with rapid stirring. The resulting precipitate was collected and recrystallized in ethanol to give the product 1,3-dimethyl-5-phenylpyrazolo[4,3-d]pyrimidine-7-one, mp 273-274°C.

Analysis as: $C_{13}H_{12}N_4O.0.5 H_2O$

Calcd: C, 62.63; H, 4.85; N, 22.48

Found: C, 62.70; H, 4.71; N, 22.41

EXAMPLE 7

1,3-Dimethyl-5-(4-chlorophenyl)pyrazolo[4,3-d]-
pyrimidine-7-one

1,3-Dimethyl-5-(4-chlorophenyl)pyrazolo[4,3-d]-
pyrimidine-7-one was made as in Example 6B us-
ing 8 g of 1,3-dimethyl-4-N-(4-chlorophenylcarbox-
amide)-pyrazole-5-carboxamide in 280 g poly-
phosphoric acid, mp 314-316°C.

Analysis as: $C_{13}H_{11}N_4OCl \cdot 0.25 H_2O$

Calcd: C, 55.56; H, 4.26; N, 19.94; Cl, 12.72

Found: C, 55.92; H, 4.15; N, 20.07; Cl, 12.70

The 1,3-dimethyl-4-N-(4-chlorophenylcarbox-
amide)-pyrazole-5-carboxamide is prepared as in
Example 6B however, using 4-chlorobenzoyl chlo-
ride for benzoic acid before cyclizing with poly-
phosphoric acid.

EXAMPLE 8

1,3-Dimethyl-5-(4-methylphenyl)pyrazolo[4,3-d]-
pyrimidine-7-one

The starting bis-amide was prepared as in Ex-
ample 4 using 5 g of 1,3-dimethyl-4-amino-
pyrazole-5-carboxamide, 5 g p-methylbenzoylch-
loride, and 3.28 g triethylamine, mp 210-211°C.

It was cyclized as in Example 43 with 200 g
polyphosphoric acid to give the product, mp 271-
272°C.

Analysis as: $C_{14}H_{14}N_4O \cdot 0.1 H_2O$

Calcd: C, 65.66; H, 5.59; N, 21.87

Found: C, 65.71; H, 5.60; N, 21.98

EXAMPLE 9

1,3-Dimethyl-5-(4-nitrophenyl)pyrazolo[4,3-d]-
pyrimidine-7-one

The bis-amide starting material was prepared
as in Example 4 using 10 g of 1,3-dimethyl-4-
amino-pyrazole-5-carboxamide, 12.04 g p-nitro-be-
nzoyl chloride and 6.55 g triethylamine, mp 283-
285°C. It was cyclized as in Example 6A using 2 g
bis-amide, 0.36 g sodium hydroxide, and 1.42 ml
30% hydrogen peroxide to give the product, mp.>

340°C.

Analysis as: $C_{13}H_{11}N_4O_3 \cdot 0.25 H_2O$.

Calcd: C, 53.87; H, 4.00; N, 24.17

Found: C, 53.83; H, 3.93; N, 23.87

EXAMPLE 10

1,3-Dimethyl-5-(4-trifluoromethylphenyl)pyrazolo-
[4,3-d]pyrimidine

The compound is prepared as in Example 6B
using 1.75 g of 1,3-dimethyl-4-aminopyrazole-5-
carboxamide, 2.16 g p-trifluoromethylbenzoic acid,
and 100 g polyphosphoric acid, and recrystallized
in ethanol, mp 286-289°C.

Analysis as: $C_{14}H_{11}N_4OF_3 \cdot 0.5 H_2O$

Calcd: C, 53.00, H, 3.81, N, 17.66

Found: C, 52.93; H, 3.99; N, 17.50

EXAMPLE 11

1,3-Dimethyl-5-(4-aminophenyl)pyrazolo[4,3-d]-
pyrimidine-7-one

The compound was prepared by catalytic re-
duction of the compound obtained in Example 9 in
aqueous base using Raney nickel. After 89% of the
theoretical amount of hydrogen was taken up, ac-
etone was added to the reaction mixture, and it
was filtered and the acetone removed. It was then
taken to pH 6 with 0.1 N HCl, and the resulting
precipitate filtered. Recrystallized from ethanol, mp
340-341°C.

Analysis as: $C_{13}H_{13}N_4O$

Calcd: C, 61.17; H, 5.13; N, 27.43

Found: C, 60.83; H, 4.90, N, 27.22

EXAMPLE 12

1,3-Dimethyl-5-(3-aminophenyl)pyrazolo[4,3-d]-
pyrimidine-7-one

The compound was prepared as in Example 11
using material from Example 13, mp 287-289°C.

Analysis as:

Calcd: C, 61.17; H, 5.13; N, 27.43

Found: C, 60.83; H, 5.42; N, 27.02

EXAMPLE 13

1,3-Dimethyl-5-(3-Mitrophenyl)pyrazolo[4,3-d]-
pyrimidine-7-one

The starting bis-amide was prepared as in Ex-
ample 4 using 10 g of 1,3-dimethyl-4-amino-
pyrazole-5-carboxamide, 12.04 g m-nitro-benzoyl-
chloride and 6.55 g triethylamine, mp 242-245°C.
This was cyclized as in Example 6A using 10 g
bis-amide, 1.98 g sodium hydroxide and 7.1 ml
30% hydrogen peroxide to give the product. This
was purified by boiling ethanol, the insoluble prot-
ion being the product, mp 334-336°C.

Analysis as $C_{13}H_{11}N_5O_3$

Calcd: C, 54.74; H, 3.89; N, 24.55

Found: C, 54.49; H, 3.95; N, 24.65

EXAMPLE 14

1,3-Dimethyl-5-(2-methoxyphenyl)pyrazolo[4,3-d]-
pyrimidine-7-one

The bis-amide was prepared as in Example 4
using 2.0 g of 1,3-dimethyl-4-aminopyrazole-5-car-
boxamide, 2.21 g of O-methoxybenzoylchloride,
and 1.31 g triethylamine, mp 217-219°C. This was
cyclized as in Example 4 using 100 g poly-
phosphoric acid to give the product, mp 222-
223.5°C.

Analysis as: $C_{14}H_{14}N_4O_2$

Calcd: C, 62.21; H, 5.22; N, 20.73

Found: C, 62.48; H, 5.50; N, 20.59

EXAMPLE 15

1,3-Dimethyl-5-(3,4-dichlorophenyl)pyrazolo[4,3-d]-
pyrimidine-7-one

The compound was prepared as in Example
6B using 7.25 g of 1,3-dimethyl-4-N-(3,4-dich-
lorophenyl) carboxamide pyrazole-5-carboxamide
in 300 g polyphosphoric acid, mp > 360°C.

Analysis as: $C_{13}H_{10}N_4OCl_2 \cdot H_2O$

10

Calcd: C, 47.73; H, 3.70; N, 17.12; Cl, 21.67

Found: C, 47.34; H, 3.52; N, 16.92; Cl, 20.84

1,3-Dimethyl-4-N-(3,4-dichlorophenyl)-
carboxamidepyrazole-5-carboxamide is prepared
as in Example 6B, however, using 3,4-dichloroben-
zoylchloride for benzoic acid before cyclizing with
polyphosphoric acid, mp 270-272°C.

EXAMPLE 16

1,3-Dimethyl-5-(3,4-dimethoxyphenyl)pyrazolo[4,3-
d] pyrimidine-7-one

25

The compound was prepared as in Example
6B using 5g of 1,3-dimethyl-4-aminopyrazole-5-car-
boxamide and 5.91 g of the commercially available
3,4-dimethoxy-benzoic acid, mp 259-260°C.

30

Analysis as: $C_{15}H_{16}N_4O_3$

Calcd: C, 59.99; H, 5.37; N, 18.66

Found: C, 59.80; H, 5.43; N, 18.29

EXAMPLE 17

1,3-Dimethyl-5-(2,4-dimethoxyphenyl)pyrazolo[4,3-
d]-pyrimidine-7-one

40

The compound was prepared as in Example
6B using 5 g of 1,3-dimethyl-4-aminopyrazole-5-
carboxamide and 5.91 g of the commercially avail-
able 2,4-dimethoxy-benzoic acid, mp 246-247°C.

45

Analysis as: $C_{15}H_{16}N_4O_3$

Calcd: C, 59.99; H, 5.37; N, 18.66

Found: C, 59.63; H, 5.42; N, 18.47

EXAMPLE 18

55

1,3-Dimethyl-5-(2-nitro-4-chlorophenyl)pyrazolo-
[4,3-d]pyrimidine-7-one

The starting bis-amide was prepared as in Ex-
ample 4 using 10 g of 1,3-dimethyl-4-aminopyrazole-5-carboxamide, 11.97 g, 2-nitro-4-chlorobenzoyl chloride, and 6.55 g triethylamine, mp 295-296°C. The bis-amide was cyclized as in Example 6A using 10.25 g bis-amide, 1.82 g sodium hydroxide, and 7.28 ml 30% hydrogen peroxide to give the product, mp 254-257°C.

Analysis as: $C_{13}H_{10}N_5O_3Cl$

Calcd: C, 48.84; H, 3.15; N, 21.91; Cl, 11.09

Found: C, 48.19; H, 3.13; N, 21.76; Cl, 11.47

EXAMPLE 19

1,3-Dimethyl-5-(2-amino-4-chlorophenyl)pyrazolo-
[4,3-d]pyrimidine-7-one

The compound was prepared by catalytic reduction as in Example 11 using material from Example 18. It was recrystallized in ethanol, mp 309-311°C.

Analysis as: $C_{13}H_{12}N_5OCl \cdot 0.25 H_2O$

Calcd: C, 53.07; H, 4.28; N, 23.80; Cl, 12.05

Found: C, 53.14; H, 4.61; N, 23.81; Cl, 10.75

EXAMPLE 20

1,3-Dimethyl-5-(4-sulfoacid phenyl)pyrazolo[4,3-d]-
pyrimidine-7-one

The compound was prepared as in Example 6B using 9 g of 1,3-dimethyl-4-amino-pyrazolo-5-carboxamide and 14 g benzoic-4-sulfonic acid in 900 g polyphosphoric acid. It was purified by recrystallization in 1:1 methanol water, mp > 360°C.

Analysis as $C_{13}H_{12}N_5O_3S$

Calcd: C, 48.75; H, 3.78; N, 17.49; S, 10.01

Found: C, 48.61; H, 3.78; N, 17.52; S, 9.84

EXAMPLE 21

1,3-Dimethyl-5-[4-(N-2-(dimethylamino)-ethylbenzenesulfonamide)pyrazolo[4,3-d]-
pyrimidine-7-one

The compound was prepared using material from Example 20. Of this, 2.67 g was suspended in DMF, and 1.98 g thionyl chloride added at 0°C. After three hours, 10 ml unsymmetrical dimethylethylenediamine was added dropwise. The reaction mixture was allowed to come to room temperature, then heated under reduced pressure. After cooling, a precipitate formed which was filtered away. Further concentration of the filtrate yielded a semisolid which was stirred in ice water. The resulting solid was recrystallized in methanol, mp 236-8°C.

Analysis as: $C_{17}H_{22}N_6O_3S \cdot 1.5 H_2O$

Calcd: C, 48.91; H, 6.03; N, 20.13; S, 8.21

Found: C, 49.11; H, 6.04; N, 20.02; S, 7.90

EXAMPLE 22

1-Ethyl-3-methyl-5-benzylpyrazolo[4,3-d]
[pyrimidine-7-one

The starting bis-amide was prepared as in Example 6A using phenylacetic acid chloride and 1-ethyl-3-methyl-4-amino-pyrazole-5-carboxamide, mp 236-236.5°C. This bis-amide was cyclized using 60 polyphosphoric acid as in Example 6B. The product was recrystallized in ethanol, mp 209-210°C.

Analysis as: $C_{18}H_{18}N_4O$

Calcd: C, 67.15; H, 6.01; N, 20.88

Found: C, 67.19; H, 5.82; N, 20.64

EXAMPLE 23

1,3-Dimethyl-5-(3,5-dimethoxyphenyl)pyrazolo[4,3-d]-
pyrimidine-7-one

The compound was prepared as in Example 6B using the product of 5 g of 1,3-dimethyl-4-aminopyrazole-5-carboxamide and 6.51 g of 3,5-dimethoxybenzoyl chloride in methylene chloride with 3.3 g triethylamine. After stirring 20 hours at ambient temperature, washing with water and concentration, the crude material was treated with

polyphosphoric acid as described. Recrystallization two times from ethanol yielded the product, mp 255-256°C.

Analysis as: $C_{15}H_{16}N_4O_3 \cdot 0.5 H_2O$

Calcd: C, 58.24; H, 5.54; N, 18.11

Found: C, 58.21; H, 5.43; N, 17.99

EXAMPLE 24

1,3-Dimethyl-5-(3-methoxyphenyl)pyrazolo[4,3-d]-pyrimidine-7-one

The compound was prepared as in Example 6A using 1.97 g of 1,3-dimethyl-5-cyanopyrazole-4-N-(3-methoxyphenyl)carboxamide, 0.44 g sodium hydroxide and 1.7 ml 30% H_2O_2 , mp 263-264°C.

Analysis as $C_{18}H_{18}N_4O_2$.

Calcd: C, 62.21; H, 5.22; N, 20.73

Found: C, 62.29; H, 5.19; N, 20.68

The starting material was prepared as in Example 6A using the corresponding acid chloride, mp 149-150°C.

EXAMPLE 25

1,3-Dimethyl-5-(2-pyridyl)pyrazolo[4,3-d]pyrimidine-7-one

The bis-amide was prepared as in Example 4 using 2.0 g of 1,3-dimethyl-4-aminopyrazole-5-carboxamide, 1.84 g picolinic acid chloride and 3.03 g triethylamine, mp 193-194°C. This was cyclized and purified as in Example 4 to give the product, mp 278-280°C.

Analysis as $C_{12}H_{11}N_5O$

Calcd: C, 59.74; H, 4.60; N, 29.03

Found: C, 59.46; H, 4.58; N, 29.08

STARTING MATERIALS

Scheme I

1,3-Dimethyl-4-nitro-pyrazole-5-carboxylic acid

One-hundred twelve g concentrated sulfuric acid is added to 42 ml 90% nitric acid at 70-80°C. 39 g of 1,3-dimethylpyrazole-5-carboxylic acid is added in portions over one hour such that the temperature does not go over 90°C. After 2.5 hours the reaction mixture is cooled and poured over ice. The resulting precipitate was filtered, dried, and recrystallized in ethanol, mp 141-142°C.

1,3-Dimethyl-4-nitropyrazole-5-carboxamide

Forty g of 1,3-dimethyl-4-nitropyrazole-5-carboxylic acid was stirred with 200 ml thionyl chloride at reflux for 3.5 hours. The excess thionyl chloride was distilled away under reduced pressure. The resulting oil was dissolved in acetone and added to icy ammonium hydroxide with stirring. The resulting precipitate was filtered and dried to give the product, mp 154-158°C.

1,3-Dimethyl-4-aminopyrazole-5-carboxamide

Fifty g of 1,3-dimethyl-4-nitropyrazole-5-carboxamide dissolved in methanol, 2 g 50% aqueous Raney nickel added, was reduced under a hydrogen atmosphere until a 8.15 pound drop in pressure noted. The reaction mixture was filtered, the filtrate concentrated, and the crude material recrystallized in ethyl acetate to yield the product, mp 154-155°C.

Scheme II

1,3-Dimethyl-4-nitro-5-cyano-pyrazole

Fifty-five g of 1,3-dimethyl-4-nitro-5-chloropyrazole was dissolved in 400 ml acetonitrile and 17.45 g potassium cyanide added, followed by 0.5 g potassium iodide and 5 ml DMF. The mixture was refluxed for 22 hours, then cooled, and filtered. The filtrate was concentrated under reduced pressure, then added to stirred water. The resulting precipitate was collected, dried, and recrystallized in isopropanol. mp, 85-87°C. A second recrystallization again in ethanol gave the product having increased purity, mp 96-98°C.

1,3-Dimethyl-4-amino-5-cyanopyrazole

Two-hundred and seventy-two g of 1,3-dimethyl-4-nitro-5-cyano-pyrazole was subjected to catalytic hydrogenation in methanol using a Raney nickel catalyst. The catalyst was filtered away and the filtrate concentrated. The product solidified, mp 109-111°C.

For Schemes I and II

1-Ethyl-3-methyl-pyrazole compounds were prepared in a strictly analogous manner to the 1,3-dimethyl compounds.

EXAMPLE 26

1,3-Dimethyl-5-(2-aminophenyl)pyrazolo[4,3-d]-pyrimidine-7-one

The compound was prepared as in Example 11 using 1,3-dimethyl-5-(2-nitrophenyl)pyrazolo[4,3-d]-pyrimidine-7-one. It was purified by recrystallizing from ethanol, mp 290-292°C.

Analysis as: $C_{13}H_{13}N_5O$

Calcd: C, 61.17; H, 5.13; N, 27.43


Found: C, 60.77; H, 5.12, N, 27.13

Starting Material for Example 26


1,3-Dimethyl-5-(2-nitrophenyl)pyrazolo[4,3-d]-pyrimidine-7-one

The starting bis-amide was prepared as in Example 6A using 10 g of 1,3-dimethyl-4-amino-pyrazole-5-carboxamide, 12 g of 2-nitrobenzoyl-chloride, and 6.55 g of triethylamine, mp 289-294°C. It was cyclized as in Example 6A using 1.29 g, sodium hydroxide and 4.62 ml of 30% hydrogen peroxide. The crude product was used in the preparation of 1,3-dimethyl-5-(2-aminophenyl)-pyrazolo[4,3-d]pyrimidine-7-one above.


FORMULA




XI




XX




XXX




I

R₂



Formula



Scheme I



SCHEME II




I

Claims

50

1. A compound having the following general formula (I):

55




and the pharmaceutically acceptable salts thereof, in which:

R₁ is a lower alkyl of from one to six carbon atoms, a lower alkenyl of from one to six carbon atoms, a lower hydroxyalkyl of from one to six carbon atoms, a lower hydroxyalkenyl of from two to six

carbon atoms, a lower aminoalkyl of from one to six carbon atoms, or a lower aminoalkenyl of from two to six carbon atoms;

n is 0 or an integer of from 1 to 4; and

Ar is a radical of the following general formula (R₂)



or 2-, 3-, or 4-pyridyl, in which X, Y, and Z are, independently, (1) hydrogen; (2) lower alkyl of from one to six carbon atoms; (3) halogen, (4) hydroxyl; (5) lower alkoxy of from one to six carbon atoms; (6) nitro; (7) amino; (8) NR'R'' wherein R' and R'' are each, independently, (a) hydrogen or (b) lower alkyl of from one to six carbon atoms optionally substituted by (i) amino, (ii) morpholino or (iii) cycloalkyl of from, five to seven carbon atoms; (9) sulfonyl; or

(10)-SO₂NR'R'' wherein R' and R'' are as defined above;

with the proviso that not all of X, Y, and Z can be nitro, amino, or NR'R'' at once.

2. A compound according to Claim 1, wherein Ar is the radical R₂ and n is 0.

3. A compound according to Claim 1, wherein Ar is 2-, 3-, or 4-pyridyl.

4. A compound according to Claim 1, wherein R₁ is methyl, Ar is the radical R₂ and n is 1.

5. A compound according to Claim 2 having one of the following names:

1-ethyl-3-methyl-5-phenylpyrazolo[4,3-d]-pyrimidine-7-one;

1,3-dimethyl-5-phenylpyrazolo[4,3-d]pyrimidine-7-one;

1,3-dimethyl-5-(4-chlorophenyl)pyrazolo[4,3-d]pyrimidine-7-one;

1,3-dimethyl-5-(4-methylphenyl)pyrazolo[4,3-d]pyrimidine-7-one;

1,3-dimethyl-5-(4-nitrophenyl)pyrazolo[4,3-d]pyrimidine-7-one;

1,3-dimethyl-5-(4-trifluoromethylphenyl)pyrazolo[4,3-d]pyrimidine;

1,3-dimethyl-5-(4-aminophenyl)pyrazolo[4,3-d]pyrimidine-7-one;

1,3-dimethyl-5-(3-aminophenyl)pyrazolo[4,3-d]pyrimidine-7-one;

1,3-dimethyl-5-(3-nitrophenyl)pyrazolo[4,3-d]pyrimidine-7-one;

1,3-dimethyl-5-(2-methoxyphenyl)pyrazolo[4,3-d]pyrimidine-7-one;

1,3-dimethyl-5-(3,4-dichlorophenyl)pyrazolo[4,3-d]pyrimidine-7-one;

1,3-dimethyl-5-(3,4-dimethoxyphenyl)pyrazolo[4,3-

d]-pyrimidine-7-one;

1,3-dimethyl-5-(2,4-dimethoxyphenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

1,3-dimethyl-5-(2-nitro-4-chlorophenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

1,3-dimethyl-5-(2-amino-4-chlorophenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

1,3-dimethyl-5-(4-sulfonic acid phenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

1,3-dimethyl-5-[4-(N-2-(dimethylamino)ethyl)benzenesulfonamide]pyrazolo[4,3-d]pyrimidine-7-one;

1,3-dimethyl-5-(3,5-dimethoxyphenyl)pyrazolo[4,3-d]-pyrimidine-7-one; or

1,3-dimethyl-5-(3-methoxyphenyl)pyrazolo[4,3-d]-pyrimidine-7-one.

6. A compound according to Claim 3 having one of the following names:

1,3-dimethyl-5-(3-pyridyl)pyrazolo[4,3-d]pyrimidine-7-one; or

1,3-dimethyl-5-(2-pyridyl)pyrazolo[4,3-d]pyrimidine-7-one.

7. A compound according to Claim 4 having one of the following names:


1,3-dimethyl-5-benzylpyrazolo[4,3-d]pyrimidine-7-one; or

1-ethyl-3-methyl-5-benzylpyrazolo[4,3-d]pyrimidine-7-one.

8. A pharmaceutical composition comprising an effective amount of a compound according to any preceding claim in admixture with a pharmaceutically acceptable carrier or diluent.

9. For use in a method of treating cardiac insufficiency in a mammal suffering therefrom, a compound as claimed in any one of Claims 1 to 7 or a pharmaceutical composition in accordance with Claim 8.


10. A process for preparing a compound of the Formula (I) according to Claim 1, which process comprises reacting a compound of the Formula - (III)



(III)

with (1) $\text{Ar}(\text{CH}_2)_n\text{CO}_2\text{H}$ and then polyphosphoric acid, or (2) $\text{Ar}(\text{CH}_2)_n\text{C}(\text{O})\text{Cl}$ and then polyphosphoric acid to obtain the compound of Formula I, wherein Ar, R₁, and n are as defined in Claim 1.

11. A process for preparing a compound of the Formula (I) according to Claim 1, which process comprises cyclizing a compound of the formula - (VII)




(VII)

with hydrogen peroxide at an elevated temperature,
wherein Ar, R, and n are as defined in Claim 1.

CLAIMS for the Contracting State : AT

1. A process for preparing a compound having the following general formula (I):




and the pharmaceutically acceptable salts thereof,
in which:

R, is a lower alkyl of from one to six carbon atoms,
a lower alkenyl of from one to six carbon atoms, a
lower hydroxyalkyl of from one to six carbon
atoms, a lower hydroxyalkenyl of from two to six

carbon atoms, a lower aminoalkyl of from one to
six carbon atoms, or a lower aminoalkenyl of from
two to six carbon atoms;

n is 0 or an integer of from 1 to 4; and

Ar is a radical of the following general formula (R₂)




or 2, 3 or 4-pyridyl, in which X, Y, and Z are,
independently, (1) hydrogen; (2) lower alkyl of from
one to six carbon atoms; (3) halogen; (4) hydroxyl;
(5) lower alkoxy of from one to six carbon atoms; -
(6) nitro; (7) amino; (8) NR'R'' wherein R' and R''
are each, independently, (a) hydrogen or (b) lower
alkyl of from one to six carbon atoms optionally
substituted by (i) amino, (ii) morpholino or (iii)
cycloalkyl of from, five to seven carbon atoms; (9)
sulfonyl; or

(10)-SO₂NR'R'' wherein R' and R'' are as defined
above;


with the proviso that not all of X, Y, and Z can be
nitro, amino, or NR'R'' at once.

which process comprises reacting a compound of
the Formula (III)



with (1) $\text{Ar}(\text{CH}_2)_n\text{CO}_2\text{H}$ and then polyphosphoric acid, or (2) $\text{Ar}(\text{CH}_2)_n\text{C}(\text{O})\text{Cl}$ and then polyphosphoric acid to obtain the compound of Formula I, wherein Ar, R, and n are as defined above.

2. A process for preparing a compound of Formula I as defined in Claim 1, which process comprises cyclizing a compound of the formula (VII)



with hydrogen peroxide at an elevated temperature, wherein Ar, R, and n are as defined in Claim 1.

3. A process according to Claim 1 or 2, wherein Ar is the radical R_2 and n is 0.

4. A process according to Claim 1, 2 or 3, wherein Ar is 2-, 3-, or 4-pyridyl.

5. A process according to any preceding claim, wherein R, is methyl, Ar is the radical R_2 and n is 1.

6. A process according to Claim 3, in which one of the following compounds is prepared:

1-ethyl-3-methyl-5-phenylpyrazolo[4,3-d]-pyrimidine-7-one;

1,3-dimethyl-5-phenylpyrazolo[4,3-d]pyrimidine-7-one;

1,3-dimethyl-5-(4-chlorophenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

1,3-dimethyl-5-(4-methylphenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

1,3-dimethyl-5-(4-nitrophenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

1,3-dimethyl-5-(4-trifluoromethylphenyl)pyrazolo[4,3-d]-pyrimidine;

1,3-dimethyl-5-(4-aminophenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

1,3-dimethyl-5-(3-aminophenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

1,3-dimethyl-5-(3-nitrophenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

15 1,3-dimethyl-5-(2-methoxyphenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

1,3-dimethyl-5-(3,4-dichlorophenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

20

1,3-dimethyl-5-(3,4-dimethoxyphenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

25

1,3-dimethyl-5-(2,4-dimethoxyphenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

30

1,3-dimethyl-5-(2-nitro-4-chlorophenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

35

1,3-dimethyl-5-(2-amino-4-chlorophenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

40

1,3-dimethyl-5-(4-sulfonic acid phenyl)pyrazolo[4,3-d]-pyrimidine-7-one;

45

1,3-dimethyl-5-[4-(N-2-(dimethylamino)ethyl)-benzenesulfonamide]pyrazolo[4,3-d]pyrimidine-7-one;

50

1,3-dimethyl-5-(3,5-dimethoxyphenyl)pyrazolo[4,3-d]-pyrimidine-7-one; or

55

1,3-dimethyl-5-(3-methoxyphenyl)pyrazolo[4,3-d]-pyrimidine-7-one.

60

7. A process according to Claim 4, in which one of the following compounds is prepared:

65

1,3-dimethyl-5-(3-pyridyl)pyrazolo[4,3-d]pyrimidine-7-one; or

70

1,3-dimethyl-5-(2-pyridyl)pyrazolo[4,3-d]pyrimidine-7-one.

75

8. A process according to Claim 5, in which one of the following compounds is prepared:

1,3-dimethyl-5-benzylpyrazolo[4,3-d]pyrimidine-7-one; or 1-ethyl-3-methyl-5-benzylpyrazolo[4,3-d]pyrimidine-7-one.

9. A process for preparing a pharmaceutical composition which process comprises combining an effective amount of a compound prepared by a process according to any preceding claim together with a pharmaceutically acceptable carrier or

diluent.

10. For use in a method of treating cardiac insufficiency in a mammal suffering therefrom, a compound prepared by a process as claimed in any one of Claims 1 to 8 or a pharmaceutical composition prepared by a process in accordance with Claim 9.

10

15

20

25

30

35

40

45

50

55